Digest Network Come funziona
Network
/
Società
Sa
Non verificato

Savara Inc.

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaMedicina - VarieSalute

59 comunicati stampa

Guarda tutti i comunicati
02/12/2025
Biotecnologia
Attrezzature medico-sanitarie
Salute
Farmaceutica
Medicina - Varie
Industria
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
20/11/2025
Biotecnologia
Farmaceutica
Salute
Eventi
Web e Social Network
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
12/11/2025
Biotecnologia
Sanità
Farmaceutica
Salute
Mercato azionario
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Biotecnologia
Farmaceutica
Finanza
Salute
Igiene alimentare
Attrezzature medico-sanitarie
Associazioni/Professionisti
Medicina - Varie
Eventi
Web e Social Network
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
31/10/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Finanza
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Comunicazione
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Titoli e azioni
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
29/10/2025
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Savara Announces Proposed Public Offering
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
29/10/2025
Mercato del lavoro
Igiene alimentare
Farmaceutica
Salute
Medicina - Varie
Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
17/10/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mercato del lavoro
Savara Announces Chief Medical Officer (CMO) Transition
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0
02/10/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Fiere
Eventi
Industria
Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025
Fonte
Savara Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0